Exelixis Inc. added increased overall survival vs. Afinitor (everolimus, Novartis AG) to the list of benefits provided by cabozantinib for second-line renal cell carcinoma (RCC) patients, providing what president and CEO Michael Morrissey told BioWorld Today was “the missing piece of the puzzle in terms of the full cabozantinib second line RCC story.”